Close Menu

Jefferies

Myriad and Cepheid discussed their pipelines, while Exact Sciences provided some details of its upcoming trial on its colon cancer test, and Danaher touted its success with past acquisitions as it nears closing of its Beckman Coulter buy.

Complete Genomics CEO Clifford Reid outlined goals for his firm, while Affymetrix CFO Tim Barabe spoke about market opportunities and a shift in the firm's business model.

Jefferies also increased the firm's stock price target to $20 from $15.50.

The Jefferies analyst also elevated the target share price for Agilent on expectations of healthy organic revenues and "immaterial" effects from the Japanese earthquake and tsunami on Agilent's business.

Jefferies analyst Jon Wood also raised his price target on the firm's stock to $15.50 from $13, following a presentation by Complete Genomics CEO Clifford Reid at a biotech conference.

Pages

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.